B+
Bull case
20%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
NERV
Minerva NeurosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$3.90
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+66.2
Score
AI commentary
The official Q2 2026 8-K confirms the Phase 3 trial remains on track and reiterates the 2H 2027 topline target, but the earnings packet does not provide consensus comparison, analyst revisions, target changes, or a verified post-print market-reaction explanation. News volume is low and peer context is loose, so this remains a cautious clinical-trial monitoring setup rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-08-07
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-07catalystHigher clinical-development spending increases runway and dilution sensitivityHigh impact
Q2 R&D expense rose to $7.2 million from $1.3 million year over year, primarily due to the C19 trial and higher compensation; G&A also increased. This supports continued financing and cash-burn monitoring [#SEC-8K-2026-08-07].
2026-11-05eventConfirmatory Phase 3 execution remains the core near-term value driverHigh impact
The MIN-101C19 global confirmatory Phase 3 trial is ongoing, designed to enroll approximately 380 patients across about 40 sites, with topline efficacy data still expected in 2H 2027. The company also expanded its Scientific Advisory Board to eleven members [#SEC-8K-2026-08-07].
2027-08-07catalystClinical readouts could materially reset the single-asset valuationHigh impact
Successful Phase A efficacy confirmation could support roluperidone as a differentiated treatment candidate for negative symptoms of schizophrenia, while Phase B relapse data are expected in 2H 2028. Both remain high-uncertainty clinical milestones [#SEC-8K-2026-08-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology